We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 21, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS
IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES
PYRIMIDINE PYRAZOLYL DERIVATIVES
FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS